Applied Antisense Oligonucleotide TechnologyISBN: 978-0-471-17279-6
Paperback
552 pages
March 1998
This is a Print-on-Demand title. It will be printed specifically to fill your order. Please allow an additional 10-15 days delivery time. The book is not returnable.
|
CHEMISTRY, OLD AND NEW.
Oligonucleoside Methylphosphonates: Synthesis and Properties (P. Miller).
Oligo(Nucleoside Phosphorothioate)s (P. Guga, et al.).
Modified Oligodeoxynucleotides as Antisense Therapeutics (P. Seeberger & M. Caruthers).
Novel Chemistry (K. Altmann, et al.).
OLIGONUCLEOTIDE INTERNALIZATION, MECHANISM OF ACTION, AND NON-SEQUENCE SPECIFICITY.
Cellular Uptake and Biodistribution of Oligodeoxynucleotides (B. Hanss, et al.).
Use of Cationic Lipid Complexes for Antisense Oligonucleotide Delivery (C. Bennett).
Nonantisense Effects of Antisense Oligonucleotides (L. Neckers & K. Iyer).
Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments (D. Tidd).
SEQUENCE-SPECIFIC INHIBITION OF GENE EXPRESSION.
The Development of C-5 Propyne Oligonucleotides as Inhibitors of Gene Function (W. Flanagan & R. Wagner).
The Use of Antisense Oligonucleotides to Inhibit Expression of Isozymes of Protein Kinase C (N. Dean, et al.).
BCR-ABL as a Target for Antisense Intervention (S. O'Brien & T. Smetsers).
The NF-kB Transcription Factor (R. Narayanan).
Disruption of the Map Kinase Signaling Pathway Using Antisense Oligonucleotide Inhibitors Targeted to RAS and RAF Kinase (B. Monia).
Protein Kinase A-Directed Antisense Blockade of Cancer Growth: Single Gene-Based Therapeutic Approach (Y. Cho-Chung).
Use of Antisense Oligonucleotides in the Central Nervous System: Why Such Success?
(M. McCarthy).
APPLIED ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS.
Perturbing Hematopoietic Cell Gene Expression with Oligodeoxynucleotides: Research and Clinical Applications (A. Gewirtz & M. Ratajczak).
BCL2 (B. Jansen & B. Brown).
Biological Activity of Guanosine Quartet-Forming Oligonucleotides (R. Rando & M. Hogan).
OLIGONUCLEOTIDES AS ANTI-HIV AGENTS.
Perspectives on Antisense Technology Against HIV (J. Gee, et al.).
In Vivo Pharmacokinetics of Oligonucleotides (S. Agrawal).
Early Clinical Trails with Gem 91, A Systemic Oligodeoxynucleotide (R. Martin).
THERAPEUTIC OLIGONUCLEOTIDE DATA BASE: PHARMACOKINETICS, IMMUNE STIMULATION, AND USE AS ANTIRESTENOTIC AGENTS.
Antisense Therapy to Inhibit Angioplasty Restenosis (L. Rabbani & W. Wang).
Pharmacokinetics of Oligonucleotides: A Review of Current Knowledge and Issues for the Future (T. Wallace & P. Cossum).
Leukocyte Stimulation by Oligodeoxynucleotides (A. Krieg).
SELECTED OLIGODEOXYNUCLEOTIDE DEVELOPMENTAL TOPICS: SPLICING AND TRIPLEXES.
Modification of Alternative Splicing of Pre-mRNA by Antisense Oligonucleotides (R. Kole).
Gene-Targeted Triple-Helix-Forming Oligonucleotides (F. Svinarchuk & C. Malvy).
Triplex-Forming Oligonucleotides for Genetic Manipulation: An Alternative View (A. Faruqi & P. Glazer).
A REVIEW OF RIBOZYME TECHNOLOGY.
Therapeutic Ribozymes: Principles, Applications, and Problems (J. Rossi).
Index.
Oligonucleoside Methylphosphonates: Synthesis and Properties (P. Miller).
Oligo(Nucleoside Phosphorothioate)s (P. Guga, et al.).
Modified Oligodeoxynucleotides as Antisense Therapeutics (P. Seeberger & M. Caruthers).
Novel Chemistry (K. Altmann, et al.).
OLIGONUCLEOTIDE INTERNALIZATION, MECHANISM OF ACTION, AND NON-SEQUENCE SPECIFICITY.
Cellular Uptake and Biodistribution of Oligodeoxynucleotides (B. Hanss, et al.).
Use of Cationic Lipid Complexes for Antisense Oligonucleotide Delivery (C. Bennett).
Nonantisense Effects of Antisense Oligonucleotides (L. Neckers & K. Iyer).
Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments (D. Tidd).
SEQUENCE-SPECIFIC INHIBITION OF GENE EXPRESSION.
The Development of C-5 Propyne Oligonucleotides as Inhibitors of Gene Function (W. Flanagan & R. Wagner).
The Use of Antisense Oligonucleotides to Inhibit Expression of Isozymes of Protein Kinase C (N. Dean, et al.).
BCR-ABL as a Target for Antisense Intervention (S. O'Brien & T. Smetsers).
The NF-kB Transcription Factor (R. Narayanan).
Disruption of the Map Kinase Signaling Pathway Using Antisense Oligonucleotide Inhibitors Targeted to RAS and RAF Kinase (B. Monia).
Protein Kinase A-Directed Antisense Blockade of Cancer Growth: Single Gene-Based Therapeutic Approach (Y. Cho-Chung).
Use of Antisense Oligonucleotides in the Central Nervous System: Why Such Success?
(M. McCarthy).
APPLIED ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS.
Perturbing Hematopoietic Cell Gene Expression with Oligodeoxynucleotides: Research and Clinical Applications (A. Gewirtz & M. Ratajczak).
BCL2 (B. Jansen & B. Brown).
Biological Activity of Guanosine Quartet-Forming Oligonucleotides (R. Rando & M. Hogan).
OLIGONUCLEOTIDES AS ANTI-HIV AGENTS.
Perspectives on Antisense Technology Against HIV (J. Gee, et al.).
In Vivo Pharmacokinetics of Oligonucleotides (S. Agrawal).
Early Clinical Trails with Gem 91, A Systemic Oligodeoxynucleotide (R. Martin).
THERAPEUTIC OLIGONUCLEOTIDE DATA BASE: PHARMACOKINETICS, IMMUNE STIMULATION, AND USE AS ANTIRESTENOTIC AGENTS.
Antisense Therapy to Inhibit Angioplasty Restenosis (L. Rabbani & W. Wang).
Pharmacokinetics of Oligonucleotides: A Review of Current Knowledge and Issues for the Future (T. Wallace & P. Cossum).
Leukocyte Stimulation by Oligodeoxynucleotides (A. Krieg).
SELECTED OLIGODEOXYNUCLEOTIDE DEVELOPMENTAL TOPICS: SPLICING AND TRIPLEXES.
Modification of Alternative Splicing of Pre-mRNA by Antisense Oligonucleotides (R. Kole).
Gene-Targeted Triple-Helix-Forming Oligonucleotides (F. Svinarchuk & C. Malvy).
Triplex-Forming Oligonucleotides for Genetic Manipulation: An Alternative View (A. Faruqi & P. Glazer).
A REVIEW OF RIBOZYME TECHNOLOGY.
Therapeutic Ribozymes: Principles, Applications, and Problems (J. Rossi).
Index.